AARTI DRUGS LTD
Add to watch list to get report alerts
BSE Code:
524348
NSE Code:
AARTIDRUGS
Business Profile
Business Profile
Aarti Drugs (AARTIDR), a pharmaceutical company, manufactures and sells bulk drugs and specialty chemicals worldwide. Part of the USD 265 million Aarti group, the company was incorporated on Sept. 28, 1984 as a private limited company and went public on July 1, 1992. Chandrakant V. Gogri is the chairman, and the managing director is Prakash M. Patil.
The company focuses on the anti-diarrhea, anti-inflammatory therapeutic groups. With eight manufacturing facilities in Tarapur and Sarigam, the company manufactures vitamins, anti-arthritis, anti-fungal, antibiotics, ACE inhibitors, anti-diabetic, anti-cholinergic, sedatives and anti-depressant drugs. It has products like Aceclofenac, Metronidazole, Ketoconazole, Ciprofloxacin HCl and Metformin HCl to name a few. The company has already commissioned and made operational its new multipurpose manufacturing facility strictly designed and built in accordance with USFDA requirements.
The manufacturing-units of ADL are GMP certified. The Company is also in the process of acquiring an ISO 9002 compliance for all units with one already approved. ADL has developed a state-of-the-art R&D center in Turbhe, Mumbai. It also have two inbuilt supporting R&D centers within the manufacturing sites which all are well recognized by Department of Science and Industrial Research, Government of India. Suyash Laboratories is a subsidiary of the company. The company has a joint venture Huanggang Yinhe Aarti Pharmaceutical Company to sell its drug ingredients in China.
The company is engaged in contract manufacturing and has developed anti-fouling agents. The company exports to more than 85 countries with clients like Sanofi?Aventis, Merck, ..etc. The registered office is at Plot No. N-198, MIDC, Tarapur, Pamtembhi village, Palghar taluka, Thane-401506, Maharashtra and corporate office at Mahendra Industrial Estate, Ground floor, Road No. 29, Plot No. 109-D, Sion (East), Mumbai-400022.
Financials
The company disclosed a sharp rise in standalone net profit for the quarter ended March 2009. During the quarter, the profit of the company rose 2.44 times to Rs 45.60 million from Rs 18.70 million in the same quarter last year. Net sales declined marginally 2.95% to Rs 1,068 million, while total income for the quarter fell marginally 3.92% to Rs 1,068.10 million, when compared with the prior year period. It reported earnings of Rs 3.90 a share during the quarter, registering 2.44 times growth over prior year period.
Recent Developments
12-APR-06
Aarti Drugs entered into a joint venture (JV) with a Chinese company to sell its drug ingredients in China. The JV will be known as Huanggang Yinhe Aarti Pharmaceutical Company.